# Becton Dickinson & Co: Form 10-Q for the period ended Jun 30, 2015

- Company: [Becton Dickinson & Co](/companies/bdx.md) (CIK 10795)
- Form: 10-Q
- Filed: 2015-08-06
- Accepted by EDGAR: Aug 6, 2015, 11:52 ET
- Period: 2015-06-30
- Accession: 0001193125-15-280441
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/10795/000119312515280441/d946027d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/10795/000119312515280441/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-04-01 to 2015-06-30 | $3.12bn | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2014-10-01 to 2015-06-30 | $7.22bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2015-04-01 to 2015-06-30 | $1.93bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2014-10-01 to 2015-06-30 | $3.94bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months, 2015-04-01 to 2015-06-30 | $178.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2014-10-01 to 2015-06-30 | $437.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2015-04-01 to 2015-06-30 | $764.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2014-10-01 to 2015-06-30 | $1.82bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-04-01 to 2015-06-30 | $137.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2014-10-01 to 2015-06-30 | $779.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-04-01 to 2015-06-30 | $105.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2014-10-01 to 2015-06-30 | $272.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-04-01 to 2015-06-30 | −$23.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2014-10-01 to 2015-06-30 | $35.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-04-01 to 2015-06-30 | $62.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2014-10-01 to 2015-06-30 | $514.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-04-01 to 2015-06-30 | $0.29 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2014-10-01 to 2015-06-30 | $2.52 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-04-01 to 2015-06-30 | $0.30 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2014-10-01 to 2015-06-30 | $2.58 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-04-01 to 2015-06-30 | 214,928,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2014-10-01 to 2015-06-30 | 204,236,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 9 months, 2014-10-01 to 2015-06-30 | $387.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2014-10-01 to 2015-06-30 | $358.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2015-06-30 | $1.56bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-06-30 | $6.30bn | us-gaap:AssetsCurrent |
| Total assets | at 2015-06-30 | $27.08bn | us-gaap:Assets |
| Current liabilities | at 2015-06-30 | $4.52bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2015-06-30 | $11.37bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2015-06-30 | $1.80bn | us-gaap:DebtCurrent |
| Shareholders' equity | at 2015-06-30 | $7.25bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2015-06-30 | 210,254,373 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 66,646 characters.

The following commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

### Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged principally in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Effective October 1, 2014, BD’s organizational structure was realigned to better complement its customer-focused solutions strategy and is now based upon two worldwide business segments, BD Medical (“Medical”) and BD Life Sciences (“Life Sciences”). The composition of the Medical segment was not changed by this realignment and the Life Sciences segment consists of the former BD Diagnostics and BD Biosciences segments. The commentary provided further below reflects this two-segment organizational structure and additional discussion regarding this organization realignment is provided in Note 6 in the Notes to Condensed Consolidated Financial Statements. CareFusion Corporation (“CareFusion”), which was acquired on March 17, 2015, operates as part of our Medical segment, as further discussed below.

BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: Europe (which includes the Middle East and Africa); Greater Asia (which includes Japan and Asia Pacific); Latin America (which includes Mexico and Brazil) and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East, Africa, Latin America and Asia Pacific. We are particularly focused on certain countries whose economic and healthcare sectors are growing rapidly, in particular: China, India, Brazil and Turkey.

### Acquisition of CareFusion

On March 17, 2015, pursuant to a definitive agreement announced on October 5, 2014, BD acquired a 100% interest in CareFusion for total consideration of approximately $12.5 billion to create a global leader in medication management and patient safety solutions. The operating activities of CareFusion from the acquisition date through March 31, 2015 were not material to BD’s consolidated results of operations and as such, CareFusion’s operating results were included in BD’s consolidated results of operations beginning on April 1, 2015. CareFusion operates as part of our Medical segment, which now includes the following organizational units, in addition to the Diabetes Care and Pharmaceutical Systems units: Medication and Procedural Solutions, which encompasses BD’s former Medical Surgical Systems unit; Medication Management Solutions; and Respiratory Solutions. Additional discussion regarding this acquisition is provided in Note 9 in the Notes to Condensed Consolidated Financial Statements and disclosures regarding BD’s financing arrangements relating to this transaction are provided in Note 14 in the Notes to Condensed Consolidated Financial Statements.

### Overview of Financial Results and Financial Condition

Third quarter revenues increased 44.6% to $3.120 billion from the prior year’s period. This increase reflected a favorable impact of 50.3% due to the inclusion of CareFusion’s sales in the current quarter’s results as well as volume increases of approximately 4.7%, partially offset by unfavorable foreign currency translation of approximately 10.4%. Pricing did not materially impact revenues for the quarter. The current-year period’s total revenues also reflected solid growth in BD’s legacy units’ sales. Third quarter Medical segment revenue growth reflected strong growth in our Medication and Procedural Solutions unit’s international sales of safety-engineered products, as well as the favorable timing of orders in the Pharmaceutical Systems unit. Medical segment revenue growth in the quarter was unfavorably impacted by lower U.S. sales growth in the Diabetes Care unit, as further discussed below, partially offset by solid sales in international markets. Revenue growth in the Life Sciences segment was primarily driven by strong sales in the Preanalytical Systems and Biosciences units. Growth in the Preanalytical Systems unit’s sales was driven by sales of safety-engineered products and sales in emerging markets. The Biosciences unit’s revenues reflected strong growth in sales of research instruments and reagents as well as the favorable timing of orders for Advanced Bioprocessing products in the United States. Third quarter sales in the United States of safety-engineered devices of $427 million increased 40.4% compared with the prior year’s quarter, primarily reflecting the inclusion of CareFusion’s sales of safety-engineered products in the current quarter’s results. Third quarter international sales of safety-engineered devices of $304 million grew 14.7% over the prior year’s period, including an estimated 18.5% unfavorable impact due to foreign currency translation. International safety-engineered device revenue growth reflected the inclusion of CareFusion’s sales of safety-engineered products in the current period’s results, as well as good performance in Western Europe.

We continue to invest in research and development, geographic expansion, and new product promotions to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including geographical expansion), develop innovative new products, and continue to improve operating efficiency and organizational effectiveness, including the integration of CareFusion. While the economic environment for the healthcare industry has stabilized, pricing pressures continue for some of our products. Healthcare utilization has stabilized and slightly improved in the United States; however, any destabilization in the future could adversely impact our U.S. businesses. Additionally, macroeconomic challenges in Europe continue to constrain healthcare utilization, although we currently view the environment as stable. In emerging markets, the Company’s growth is dependent primarily on government funding for healthcare systems.

Our financial position remains strong, with cash flows from operating activities totaling $1.052 billion in the first nine months of fiscal year 2015. At June 30, 2015, we had $1.6 billion in cash and equivalents and short-term investments. We continued to return value to our shareholders in the form of dividends. During the first nine months of fiscal year 2015, we paid cash dividends of $358 million. No shares were repurchased during the first nine months of fiscal year 2015 and no share repurchases are planned for the remainder of fiscal year 2015 as our share repurchase program has been suspended in connection with the CareFusion acquisition.

Each reporting period, we face currency exposure that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. The ongoing strengthening of the U.S. dollar resulted in an unfavorable foreign currency translation impact to our revenue growth during the quarter, as discussed above. We evaluate our results of operations on both a reported and a foreign currency-neutral basis, which excludes the impact of fluctuations in foreign currency exchange rates. From time to time, we may purchase forward contracts and options to partially protect against adverse foreign exchange rate movements. Gains or losses on our derivative instruments are largely offset by the gains or losses on the underlying hedged transactions. We do not enter into derivative instruments for trading or speculative purposes. For further discussion, refer to Note 12 in the Notes to Condensed Consolidated Financial Statements.

Reflected in the financial results for the three and nine-month periods of fiscal years 2015 and 2014 are the following specified items:

| (Millions of dollars) | Three months ended June 30, 2015 | 2014 |  | Nine months ended June 30, 2015 | 2014 |  |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Financing costs (A) | $5 | $— |  | $107 | $— |  |
| Transaction costs (A) | 9 | — |  | 52 | — |  |
| Integration costs (A) | 24 | — |  | 55 | — |  |
| Restructuring costs (A) | 75 | — |  | 136 | — |  |
| Purchase accounting adjustments | 439 (B) | 19 | (D) | 466 (C) | 56 | (D) |
| Employee termination cost-related amounts (E) | (5) | — |  | (5) | — |  |
| Research and development charges (F) | — | 9 |  | — | 29 |  |
| Litigation-related charge (G) | — | — |  | 12 | — |  |
| Other specified items, net (H) | — | — |  | — | 2 |  |
| Total specified items | 548 | 28 |  | 824 | 88 |  |
| Tax impact of specified items | 169 | 10 |  | 277 | 29 |  |
| After-tax impact of specified items | $379 | $19 |  | $547 | $59 |  |

(A) Represents financing, transaction, integration and restructuring costs associated with the CareFusion acquisition. The financing costs were recorded in *Interest expense*. The transaction, integration and restructuring costs were recorded in *Acquisition-related costs*. For further discussion, refer to Note 9 in the Notes to Condensed Consolidated Financial Statements.

(B) Represents non-cash amortization expense of $148 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of $291 million pre-tax to reflect CareFusion’s inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. BD’s amortization expense is primarily recorded in *Costs of products sold.*

(C) Represents non-cash amortization expense of $184 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase accounting adjustments of $291 million pre-tax to reflect CareFusion’s inventory, fixed assets, debt and deferred revenue balances at fair value as of the acquisition date. The adjustment also reflected a pre-tax acquisition-date accounting gain of $9 million on the previously held investment in CRISI Medical Systems, Inc., a company BD fully acquired in March 2015.

(D) Includes the non-cash expense associated with the amortization of acquisition-related identifiable intangible assets.

(E) Represents an adjustment to decrease the liability for employee termination costs recorded relative to workforce reduction actions taken in the fourth quarter of fiscal year 2014. For further discussion, refer to Note 8 in the Notes to Condensed Consolidated Financial Statements.

(F) Includes a $9 million charge associated with the decision to terminate a research and development program in the Medical segment; the charge relates to program asset write-offs and obligations. The amount for the nine months ended June 30, 2014 additionally includes a $20 million charge recorded by our Life Sciences segment for asset write-offs primarily resulting from the discontinuance of an instrument product development program. The asset write-offs were largely attributable to capitalized product software, but also included a lesser amount attributable to fixed assets.

(G) Represents a charge for RTI’s attorneys’ fees, recorded in *Selling and administrative expense,* associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit RTI filed against BD. For further discussion, refer to Note 5 in the Notes to Condensed Consolidated Financial Statements.

(H) Includes an $11 million charge recorded by our Life Sciences segment in *Selling and administrative expense* for contract termination costs that resulted from the early termination of a European distributor arrangement. Also includes a gain of $8 million in *Other income (expense), net*, resulting from the sale of a company in which we held a small equity ownership interest.

### Results of Operations

### Revenues

Refer to Note 6 in the Notes to Condensed Consolidated Financial Statements for segment financial data.

#### Medical Segment

The following is a summary of third quarter Medical revenues by organizational unit:

| (Millions of dollars) | Three months ended June 30, 2015 | 2014 | Total Change | Estimated FX Impact |
| --- | ---: | ---: | ---: | ---: |
| Medication and Procedural Solutions | $848 | $590 | 43.8% | (8.4)% |
| Medication Management Solutions | 554 | — | NM | NM |
| Diabetes Care | 245 | 258 | (5.2)% | (8.6)% |
| Pharmaceutical Systems | 333 | 353 | (5.5)% | (13.5)% |
| Respiratory Solutions | 232 | — | NM | NM |
| Deferred revenue adjustment (A) | (13) | — | NM | NM |
| Total Medical Revenues | $2,199 | $1,201 | 83.1% | (12.4)% |

(A) Represents the amortization of the acquisition-date write-down of CareFusion’s deferred revenue balance to reflect a fair value measurement as of the acquisition date. The write-down primarily related to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.

Medical segment revenue growth in the current quarter largely reflected the inclusion of CareFusion’s sales in the current period’s results beginning on April 1, 2015. Segment revenue growth additionally reflected strong growth in international sales of flush and safety-engineered products in our Medication and Procedural Solutions unit, which includes our former Medical Surgical Systems unit. Revenue growth for the Diabetes Care unit was unfavorably impacted by lower sales growth in the United States due primarily to the slowing of the conversion from syringes to pen needles and the flattening of price trends. This unfavorable impact to the Diabetes Care unit’s revenues in the quarter was partially offset by solid sales in international markets. The Pharmaceutical Systems unit’s revenue growth reflected a favorable timing of orders during the quarter. Global sales of safety-engineered products were $456 million, as compared with $284 million in the prior year’s quarter, reflecting the inclusion of CareFusion’s sales in the current quarter’s results. Global sales of safety-engineered products in the quarter also included an estimated $27 million unfavorable impact due to foreign currency translation. Total Medical revenues for the nine-month period ended June 30, 2015 increased by 29.5% from the prior-year nine-month period, reflecting the inclusion of CareFusion’s current quarter’s sales in the current year-to-date period’s results and an estimated 7.5% unfavorable impact from foreign currency translation. For the nine-month period ended June 30, 2015, global sales of safety-engineered products were $1.033 billion, compared with $832 million in the prior year’s period, reflecting the inclusion of CareFusion’s safety-engineered sales in the current quarter’s results. Global sales of safety-engineered products in the nine-month period also included an estimated $47 million unfavorable impact due to foreign currency translation.

Medical operating income for the third quarter was $483 million, or 22.0% of Medical revenues, compared with $356 million, or 29.7% of segment revenues, in the prior year’s quarter. Gross profit margin was lower in the current quarter as compared with the third quarter of 2014 due to the amortization of intangible assets acquired in the CareFusion transaction and the amortization of the acquisition-date write-down of CareFusion’s deferred revenue balance, as previously discussed. These unfavorable impacts on gross margin were partially offset by lower manufacturing costs resulting from continuous improvement projects. Aggregate selling and administrative expense for the third quarter primarily reflected the inclusion of CareFusion’s spending in the current quarter’s results. Medical segment selling and administrative expense for the third quarter also included the depreciation of the fair value step-up adjustment recorded upon the acquisition date relative to CareFusion’s fixed assets. Research and development expenses for the quarter increased $38 million, or 70% above the prior year’s period. This increase is primarily attributable to the inclusion of CareFusion’s costs in the current period’s results, partially offset by a favorable comparison to the prior year period which included a $9 million charge associated with the decision to terminate a research and development program, as previously discussed. Segment operating income for the nine-month period was $1.115 billion, or 25.5% of Medical revenues, compared with $968 million, or 28.6%, in the prior year’s period.

#### Life Sciences Segment

The following is a summary of third quarter Life Sciences revenues by organizational unit:

| (Millions of dollars) | Three months ended June 30, 2015 | 2014 | Total Change | Estimated FX Impact |
| --- | ---: | ---: | ---: | ---: |
| Preanalytical Systems | $349 | $364 | (4.0)% | (8.1)% |
| Diagnostic Systems | 302 | 315 | (4.2)% | (7.9)% |
| Biosciences | 269 | 277 | (2.7)% | (7.8)% |
| Total Life Sciences Revenues | $921 | $956 | (3.7)% | (7.9)% |

Life Sciences segment revenue growth for the quarter was primarily driven by growth in the Preanalytical and Biosciences units. Revenue growth in the Diagnostic Systems unit reflected solid growth in sales of core microbiology platforms and double-digit growth in sales of the BD Max™ molecular platform, partially offset by the impact of guidelines providing for increased Pap smear testing intervals and continued pressure on sales of the BD ProbeTec™ ET and BD Viper™ platforms. The Preanalytical Systems unit’s revenue growth was driven by sales of safety-engineered products and sales in emerging markets. Global sales of safety-engineered products in the Preanalytical Systems unit totaled $275 million, compared with $285 million in the prior year’s quarter, and included an estimated $23 million unfavorable impact due to foreign currency translation. The Biosciences unit’s revenue growth reflected strong growth in sales of research instruments and reagents as well as the favorable timing of orders for Advanced Bioprocessing products in the United States. Total Life Sciences revenues for the nine-month period ended June 30, 2015 decreased by 0.6% from the prior-year nine-month period, including an estimated 5.7% unfavorable impact from foreign currency translation. For the nine-month period ended June 30, 2015, global sales of safety-engineered products in the Preanalytical Systems unit were $822 million, compared with $825 million in the prior year’s period, and included an estimated $46 million unfavorable impact due to foreign currency translation.

Life Sciences operating income for the third quarter was $197 million, or 21.4% of Life Sciences revenues, compared with $221 million, or 23.1% of segment revenues, in the prior year’s quarter. Gross profit margin was lower in the third quarter of fiscal year 2015 compared with the third quarter of 2014 primarily due to unfavorable foreign currency translation, as well as other various immaterial items. Selling and administrative expense as a percentage of Life Sciences revenues in the third quarter of 2015 was slightly lower compared with the third quarter of 2014, due to various immaterial items. An increase in research and development expense in the third quarter of 2015 of $5 million, or 7.5%, primarily reflected the timing of project spending as well as increased investment in new products and platforms. Segment operating income for the nine-month period was $610 million, or 21.4% of Life Sciences revenues, compared with $653 million, or 22.8%, in the prior year’s period.

#### Geographic Revenues

BD’s worldwide third quarter revenues by geography were as follows:

| (Millions of dollars) | Three months ended June 30, 2015 | 2014 | Total Change | Estimated FX Impact |
| --- | ---: | ---: | ---: | ---: |
| United States | $1,693 | $871 | 94.4% | — |
| International | 1,427 | 1,286 | 10.9% | (17.5)% |
| Total Revenues | $3,120 | $2,157 | 44.6% | (10.4)% |

U.S. revenue growth in our Medical segment reflected the inclusion of CareFusion’s sales in the current year’s quarter. U.S. Medical segment growth was unfavorably impacted by weaker U.S. sales in the Diabetes Care unit and an unfavorable comparison to the prior-year period for the Pharmaceutical Systems unit due to relatively strong sales in the prior-year period. U.S. Life Sciences revenue growth reflected strong growth in sales of research instruments and reagents, as well as the favorable timing of orders for Advanced Bioprocessing products in the Biosciences unit. U.S. Life Sciences revenue growth also reflected continued growth in the Diagnostic Systems unit’s sales of its core microbiology platforms and its BD MaxTM molecular platform, partially offset by the impact of increased testing intervals, as previously discussed, and continued pressure on sales of the unit’s BD Probe TecTM ET and BD ViperTM platforms in the United States.

International revenue growth in the Medical segment reflected the inclusion of CareFusion’s sales in the current year’s quarter. International Medical growth also reflected strong performance in the Pharmaceutical Systems unit’s international sales as well as in the Medication and Procedural Solutions unit’s sales of its safety engineered products. The Diabetes Care unit’s revenues reflected solid sales in international markets. International revenue growth in the Life Sciences segment reflected strong growth in the Preanalytical Systems and Diagnostic Systems units. Emerging market revenues for the third quarter of $539 million represented an increase of 1.6% over the prior year’s quarter, including a 9.4% unfavorable impact due to foreign currency translation. Revenue growth in emerging markets for the third quarter was driven by sales in Latin America and China.

### Gross Profit Margin and Operating Expenses

A summary of gross profit margin, selling and administrative expense and research and development expense for the three and nine months ended June 30, 2015 and 2014 is as follows:

| (Millions of dollars) | Three months ended June 30, 2015 | 2014 | Nine months ended June 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Gross profit margin % | 38.1% | 51.5% | 45.4% | 51.2% |
| Selling and administrative expense | $764 | $528 | $1,820 | $1,584 |
| % of revenues | 24.5% | 24.5% | 25.2% | 25.4% |
| Research and development expense | $178 | $137 | $437 | $410 |
| % of revenues | 5.7% | 6.4% | 6.0% | 6.6% |

32

#### Gross profit margin

The decrease in gross profit margin for the third quarter of fiscal year 2015 compared with the prior-year period in 2014 primarily reflected an unfavorable impact of 1,230 basis points due to the recognition of the fair value step-up adjustment recorded relative to CareFusion’s inventory on the acquisition date as well as the amortization and depreciation of intangible and fixed assets, respectively, that were acquired in the CareFusion transaction. For further discussion regarding the inventory and intangible assets acquired in the CareFusion transaction, refer to Note 9 in the Notes to Condensed Consolidated Financial Statements. The decrease in gross profit margin for the third quarter of fiscal year 2015 also reflected an estimated unfavorable impact of 140 basis points relating to foreign currency translation. The favorable impact in the current year’s quarter from operating performance of 30 basis points was primarily driven by lower manufacturing costs from continuous improvement projects and lower raw material costs, partially offset by higher pension costs.

The decrease in gross profit margin for the nine-month period reflected an unfavorable impact of 540 basis points due to the inventory step-up adjustment, intangible asset amortization and fixed asset depreciation impacts noted above. Gross margin for the current nine-month period also reflected an estimated unfavorable impact of 70 basis points relating to foreign currency translation and a favorable operating performance impact of approximately 30 basis points. Operating performance in the nine-month period reflected lower manufacturing costs from continuous improvement projects, favorable product mix and lower raw material costs, partially offset by higher pension costs and price decreases.

#### Selling and administrative expense

Aggregate expenses in the current year’s period primarily reflected the inclusion of CareFusion’s selling and administrative expenses in the current quarter’s results, as well as depreciation of the fair value step-up adjustment recorded upon the acquisition date relative to CareFusion’s fixed assets. Selling and administrative expense for the third quarter of fiscal year 2015 was favorably impacted by foreign currency translation of approximately $46 million.

Aggregate expenses for the current nine-month period reflected the inclusion of CareFusion’s selling and administrative expenses in the current quarter’s results, as well as the depreciation of the fair value step-up adjustment, as noted above. Selling and administrative expense in the current year’s nine-month period was favorably impacted by foreign currency translation of approximately $88 million. Aggregate expenses for the current year’s nine-month period also included increased spending of $38 million relating to the expansion of our business in emerging markets and the global enterprise resource planning initiative to update our business information systems, as well as a $12 million charge relating to the RTI litigation matter, as previously discussed. Aggregate expenses in the prior year’s nine-month period included the $11 million charge relating to the early termination of a distributor arrangement previously discussed as well as the favorable impact of a $6 million reversal of bad debt expense that was recorded upon receiving a payment relating to outstanding receivables due from the Spanish government.

#### Research and development expense

The increase in research and development expense for the third quarter, compared with the prior year’s period, reflected the inclusion of CareFusion’s research and development expenses in the current quarter’s results. BD’s spending in the current year’s quarter relative to its legacy units was slightly lower due to the timing of projects. Research and development expense in the prior period’s quarter reflected a $9 million charge associated with the decision to terminate a research and development program in the Medical segment, as previously discussed.

The increase in research and development expense for the nine-month period reflected the inclusion of CareFusion’s current quarter’s research and development expenses in the current quarter’s results. Research and development expenses in the current nine-month period also reflected a favorable comparison to the prior-year period’s expense, which included the program termination in the Medical segment, as noted above, as well as the $20 million asset write-off charge recorded in the second quarter of fiscal year 2014 upon the discontinuance of a program in the Life Sciences segment, as previously discussed.

#### Acquisition-related costs

Acquisition-related costs were $108 million in the third quarter of fiscal year 2015, which reflected transaction, integration and restructuring costs of $9 million, $24 million and $75 million, respectively. Acquisition-related costs in the nine-month period ending June 30, 2015 were $244 million which reflected transaction, integration and restructuring costs of $52 million, $55 million and $136 million, respectively. The transaction and integration costs in both the three and nine-month periods reflected advisory, legal, and other costs incurred in connection with the CareFusion acquisition. The restructuring costs in the current quarter reflected employee termination costs, share-based compensation expense and other restructuring costs relating to the acquisition. For further discussion regarding these costs, refer to Notes 7, 8 and 9 in the Notes to Condensed Consolidated Financial Statements.

### Net Interest Expense

The components of net interest expense were as follows:

| (Millions of dollars) | Three months ended June 30, 2015 | 2014 | Nine months ended June 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $(105) | $(33) | $(272) | $(99) |
| Interest income | 2 | 12 | 20 | 36 |
| Net interest expense | $(103) | $(20) | $(252) | $(63) |

The increases in interest expense for the three and nine-month periods of fiscal year 2015 compared with the prior year periods primarily reflected increased financing costs associated with the CareFusion acquisition, including interest on $6.2 billion of senior unsecured notes issued in December 2014, in anticipation of closing the CareFusion acquisition. Interest expense for the current year’s periods also reflected $8 million due to the favorable amortization of the acquisition-date fair value-step recorded on CareFusion’s long-term debt, partially offset by $5 million of costs associated with our April 2015 exchange of CareFusion notes assumed in the acquisition for BD notes. Interest expense in the current nine-month period additionally included commitment fees for a bridge loan facility entered into concurrently with the execution of the agreement to acquire CareFusion to ensure our ability to fund the cash portion of consideration due under the agreement. Additional disclosures regarding the debt issuance, exchange offer and bridge loan facility are provided in Note 14 in the Notes to Condensed Consolidated Financial Statements.

The decreases in interest income in the current year’s three and nine-month periods compared with the prior year’s periods primarily reflected lower cash levels outside of the United States as well as lower investment gains on assets related to our deferred compensation plans. The offsetting movements in the deferred compensation plan liability were recorded in *Selling and administrative expense.*

### Income Taxes

The income tax rate was (60.0)% for the third quarter of fiscal year 2015 compared with 23.0% in the third quarter of fiscal year 2014. The effective income tax rate for the current year’s quarter would have been higher by 8,480 basis points excluding the impact on BD’s income mix of the previously discussed specified items. The tax benefits on these specified items were primarily incurred in higher tax jurisdictions. The nine-month tax rate was 6.4% compared with the prior year’s rate of 22.8%. The effective income tax rate for the current year’s nine-month period would have been higher by 1,630 basis points excluding the impact on BD’s income mix of the third quarter specified items, which, as discussed above, were affected by higher tax benefits, as well as the impact of previously discussed specified items recorded in the first and second quarters of fiscal year 2015. The decrease in the income tax rate for the nine-month period of 2015 additionally reflected the extension of the U.S. research and development income tax credit, which was partially offset by the unfavorable impact of one-time discrete items.

### Net Income and Diluted Earnings per Share

Net income and diluted earnings per share for the third quarter of 2015 were $62 million and $0.29, respectively. Net income and diluted earnings per share for the prior year’s third quarter were $326 million and $1.65, respectively. The current quarter’s earnings per share reflected an unfavorable impact of $1.76 relating to the previously discussed specified items, as well as an estimated unfavorable impact due to foreign currency translation of $0.29. Net income and diluted earnings per share for the nine-month period of 2015 were $514 million and $2.52, respectively, compared with $884 million and $4.47, respectively, in the prior year’s period. The current year-to-date period’s earnings per share reflected an unfavorable impact of $2.68 relating to the previously discussed specified items, as well as an estimated unfavorable impact due to foreign currency translation of $0.52. Additionally, diluted earnings per share for nine-month period of 2015 reflected a dilutive impact of $0.02 from the shares BD issued, as part of the total consideration transferred upon the closing of the CareFusion acquisition, prior to the inclusion of CareFusion in our consolidated results of operations.

### Liquidity and Capital Resources

### Net Cash Flows from Operating Activities

Cash generated from operations, along with available cash and cash equivalents, is expected to be sufficient to fund our normal operating needs for the remainder of fiscal year 2015. Normal operating needs in fiscal year 2015 include working capital, capital expenditures, and cash dividends. Net cash provided by operating activities was $1.052 billion during the first nine months of fiscal year 2015, compared with $1.207 billion in the same period in 2014, reflecting a decrease in income from operations, as adjusted for depreciation and amortization. The current-period change in operating assets and liabilities was a net use of cash and primarily reflected higher levels of accounts receivables and prepayments and lower levels of accounts payable and accrued expenses, partially offset by lower levels of inventory. The lower levels of inventory reflected the impact of the third quarter fiscal year 2015 recognition of the acquisition fair value step-up adjustment recorded relative to CareFusion’s inventory on the acquisition date. Net cash provided by operating activities in the first nine months of both fiscal years 2015 and 2014 was reduced by changes in the pension obligation resulting primarily from discretionary cash contributions of $40 million and $75 million in the first nine months of fiscal years 2015 and 2014, respectively.

### Net Cash Flows from Investing Activities

Net cash used for investing activities for the first nine months of the current year was $8.003 billion, compared with $730 million in the prior-year period. Cash inflows from the sales of investments of $837 million were attributable to the maturities of time deposits in Europe, Latin America and Asia Pacific. Cash outflows relating to acquisitions of $8.3 billion were primarily attributable to the completion of the CareFusion acquisition in the second quarter of fiscal year 2015. Cash outflows relating to acquisitions in the current year’s nine-month period also included cash payments relating to other acquisitions, including GenCell Biosystems, CRISI Medical Systems, Inc. and the ARX group of companies in the first, second and third quarters of fiscal year 2015, respectively. Cash outflows relating to acquisitions were $40 million in the first nine months of the prior year as a result of the Company’s acquisition of Alverix, Inc. in the second quarter of fiscal year 2014. Capital expenditures were $387 million in the first nine months of fiscal year 2015 compared with $339 million in the prior-year period.

### Net Cash Flows from Financing Activities

Net cash provided by financing activities for the first nine months of fiscal year 2015 was $6.667 billion, compared with net cash used for financing activities of $701 million in the prior-year period.

#### Debt-related Activities

Net cash provided by financing activities in the current period included the proceeds from $6.2 billion of notes issued in December 2014 as well as $850 million total proceeds from net borrowings under commercial paper programs and a term loan facility. These proceeds were used to finance the completion of our acquisition of CareFusion in March 2015. For additional information regarding these financing arrangements, refer to Note 14 in the Notes to Condensed Consolidated Financial Statements and for additional information regarding the CareFusion acquisition, refer to Note 9 in the Notes to Condensed Consolidated Financial Statements.

Certain measures relating to our total debt, which was $13.2 billion at June 30, 2015 and $4.0 billion at September 30, 2014, were as follows:

|  | June 30, 2015 | September 30, 2014 |
| --- | ---: | ---: |
| Short-term debt as a percentage of total debt | 13.7% | 5.1% |
| Weighted average cost of total debt | 3.2% | 3.7% |
| Total debt as a percentage of total capital\* | 58.3% | 43.4% |

\* Represents shareholders’ equity, net non-current deferred income tax liabilities, and debt.

The ratio of short-term debt as a percentage of total debt at June 30, 2015 reflected the reclassification, from long-term debt to short-term debt, of $750 million of floating rate notes due on June 15, 2016.

#### Repurchase of Common Stock

There were no share repurchases during the first nine months of fiscal year 2015 as our share repurchase program has been suspended throughout fiscal year 2015 beginning with our announced agreement to acquire CareFusion. For the first nine months of fiscal year 2014, we repurchased approximately 3.6 million shares of our common stock for $400 million. At June 30, 2015, a total of approximately 9.1 million common shares remained available for purchase under the Board of Directors’ September 2013 repurchase authorization.

### Cash and Short-term Investments

At June 30, 2015, total worldwide cash and short-term investments were approximately $1.6 billion, of which $849 million was held in jurisdictions outside of the United States. We regularly review the amount of cash and short-term investments held outside the United States and currently intend to use such amounts to fund our international operations and their growth initiatives. In addition, if these amounts were repatriated from foreign jurisdictions to the United States, there could be adverse tax consequences.

### Credit Facilities

In January 2015 and in connection with our agreement to acquire CareFusion, we entered into a commercial paper program which allows us to issue a maximum of $1 billion in notes. A former commercial paper program which had been in place to meet short-term financing needs was terminated in February 2015 and the outstanding borrowings of $200 million under the former program were rolled into the new commercial paper program. Also in connection with the CareFusion acquisition, we entered into a 364-day term loan agreement in December 2014 that provides for a $1.0 billion term loan facility. Under the financial covenants of the term loan facility, BD is required to maintain an interest expense coverage ratio (ratio of earnings as defined under the agreement to interest expense) of not less than 5-to-1 as of the last day of any fiscal quarter. Additionally,

BD is required to maintain a leverage ratio (ratio of debt to earnings as defined under the agreement) as of the last day of any fiscal quarter of no greater than 4.75-to-1. We were in compliance with these covenants as of June 30, 2015.

At June 30, 2015, subsequent to the completion of the CareFusion acquisition on March 17, 2015, borrowings outstanding under the current commercial paper program were $700 million. At June 30, 2015, borrowings outstanding under the term loan agreement were $350 million reflecting a $650 million principal payment made in April 2015. In July 2015, we made a $250 million principal payment to further reduce the outstanding balance on the term loan facility. The $9.1 billion of fully committed bridge financing we secured in the first quarter of fiscal year 2015, concurrently with our execution of the agreement to acquire CareFusion, was terminated upon completion of the acquisition. Additional disclosures regarding BD’s financing arrangements relating to the CareFusion acquisition are provided in Note 14 in the Notes to Condensed Consolidated Financial Statements.

We have available a $1 billion syndicated credit facility with an expiration date of May 2018. This credit facility, under which there were no borrowings outstanding at June 30, 2015, provides backup support for our commercial paper programs and can also be used for other general corporate purposes. It includes a provision that enables BD, subject to additional commitments made by the lenders, to access up to an additional $500 million in financing through the facility for a maximum aggregate commitment of $1.5 billion. The credit facility includes a single financial covenant that requires BD to maintain an interest expense coverage ratio of not less than 5-to-1 for the most recent four consecutive fiscal quarters. We were in compliance with this covenant as of June 30, 2015. In addition to the U.S. credit facilities discussed above, we have informal lines of credit outside the United States.

### CareFusion Debt Assumed

Upon the closing of the CareFusion acquisition in March 2015, BD assumed senior unsecured notes issued by CareFusion with an aggregate principal amount of $2 billion. Subsequent to closing the acquisition, BD commenced offers to exchange these CareFusion notes for notes issued by BD and this exchange offer expired in April 2015. Additional disclosures regarding this exchange offer are provided in Note 14 in the Notes to Condensed Consolidated Financial Statements.

### Access to Capital and Credit Ratings

Subsequent to BD’s announcement regarding our acquisition of CareFusion, the two major corporate debt rating organizations, Moody’s Investors Service (Moody’s) and Standard & Poor’s Ratings Services (S&P), provided guidance that they expected to downgrade our debt ratings as a result of the anticipated increase in BD’s net leverage. In December 2014, S&P downgraded BD’s long-term debt and commercial paper ratings from A to BBB+ and from A-1 to A-2, respectively. Following our announced completion of the CareFusion acquisition on March 17, 2015, Moody’s converted its provisional downgrade of BD’s long-term debt rating, from A3 to Baa2, to a definitive downgrade. Concurrently with these downgrade actions, BD’s ratings with both S&P and Moody’s were removed from further review.

BD’s credit ratings remain investment grade after these downgrades. As such, we do not expect these downgrades to have a significant impact on our liquidity or future flexibility to access additional liquidity given our strong balance sheet, our syndicated credit facility, and our commercial paper program. While such downgrades in our credit ratings may increase the costs associated with maintaining and borrowing under our existing credit arrangements, the downgrades do not affect our ability to draw on these credit facilities, nor do they result in an acceleration of the scheduled maturities of any outstanding debt. We believe that given our debt ratings, our financial management policies, our ability to generate cash flow and the non-cyclical, geographically diversified nature of our businesses, we would have access to additional short-term and long-term capital should the need arise. A rating reflects only the view of a rating agency and is not a recommendation to buy, sell or hold securities. Ratings can be revised upward or downward at any time by a rating agency if such rating agency decides that circumstances warrant such a change.

### Concentrations of Credit Risk

We continually evaluate our accounts receivables for potential collection risks particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. Due to recent economic conditions and other factors in certain European countries, the average length of time it has taken us to collect government receivables in these countries has been longer than the payment patterns experienced in the United States and other international markets. We continually monitor these government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. We believe the current reserves related to these government receivables are adequate and that this concentration of credit risk will not have a material adverse impact on our financial position or liquidity. Specifically relative to the recent economic developments in Greece, potential exposures to our revenues, accounts receivable and other assets are not material.

### Update of Critical Accounting Policies

The preparation of the consolidated financial statements requires management to use estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Some of those judgments can be subjective and complex and, consequently, actual results could differ from those estimates. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. For any given estimate or assumption made by management, it is possible that other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Actual results that differ from management’s estimates could have an unfavorable effect on our consolidated financial statements. Upon our acquisition of CareFusion on March 17, 2015, we have implemented the following critical accounting policies. There have been no other material changes to our critical accounting policies since September 30, 2014.

### Accounting for Sales-Type Leases

Our accounting for sales-type leases is based upon certain assumptions including the economic life of our leased products and the fair value of our leased products, which is used to determine the interest rate implicit to the lease. These assumptions affect that amount of gross investment in the lease, unearned income, and the sales price that is recognized relative to each sales-type lease transaction. Based upon our anticipation of future technological advances of our products or that of our competitors, the economic life of our leased products is five years as this is the estimated period during which the leased product is expected to be economically usable, without limitation by the lease term. Additionally, five years represents the most frequent contractual lease term for our leased products. Our product configurations are customized for each customer’s specific specifications, and as such, there is no significant after-market for our used equipment. Residual values, if any, are established at lease inception using estimates of the fair value of reclaimable component parts of the products at the end of the lease term.

The fair value of our leased products is estimated on a quarterly basis, based upon transacted cash sales prices during the preceding twelve-month period, and represents normal selling price, reflecting any volume or trade discounts that may apply. Because our products are sold as part of customized systems to a diverse range of customers, many of which are affiliated with a group purchasing organization or integrated delivery network, there is a wide range of negotiated cash selling prices for our products. Accordingly, we stratify our cash selling transactions based on product configuration and customer class to determine a best estimate of fair value for each product specific, within determined customer classes. Based upon this stratification, we calculate the weighted average selling price of each configured product using the interquartile range methodology and remove outliers from the population of normal cash selling prices, which narrows the range of selling prices within each stratified customer class. The resulting weighted average selling price is the single point estimate of fair value that we use as the normal selling price and this fair value estimate is used to determine the implicit interest rate for each product subject to a sales-type lease arrangement. The interest rate implicit to the lease is then used to determine the amount of revenue recognized at the inception of the lease and the revenue recognized over the life of the lease.

Approximately 15-25% of our lease transactions in a given year do not have corresponding cash selling transactions for the same product configuration and customer class. Therefore, for these transactions, the estimated fair value is determined by: (1) reviewing the estimated fair value of the same product line with the closest similar configuration sold to the same customer class and adjusting this fair value by the expected pricing impact of the difference in product configuration; or (2) reviewing the estimated fair value of the same product configuration sold to a different customer class and adjusting this fair value by the expected pricing impact of the difference in customer class.

Our net investment in sales-type leases primarily arises from the leasing of dispensing equipment and as such, the methodology for determining the relating allowance for credit losses is based on the collective population and is not stratified by class or portfolio segment. The allowance for credit losses is based on historical experience loss rates as well as on management’s judgments regarding the potential impact of anticipated changes in business practices, market dynamics, and economic conditions. These assumptions are inherently subjective and it is possible that we will experience actual credit losses that are different from our current estimates.

### Accounting for Software Products

We sell and lease products with embedded software and as such, we must evaluate these products to determine if industry-specific revenue recognition requirements apply to these sales transactions. This evaluation process is often complex and subject to significant judgment. If software is considered not essential to the non-software elements of a product but is considered more than incidental to a product as a whole, the product’s software elements must be separated from its non-software elements under the requirements relating to multiple-element arrangements. The product’s software elements must be accounted for under software industry-specific revenue recognition requirements and the application of these requirements may significantly affect the timing and amount of revenue recognized.

We have determined that the software embedded within our infusion products, when sold with safety software, patient identification products, and certain diagnostic equipment, as well as the software embedded within our research and clinical instruments sold by our Biosciences unit, is more than incidental to these product offerings as a whole. However, we have determined that the non-software elements and software elements in these product offerings work together to deliver the essential functionality of these products as a whole. As such, the accounting for these product offerings does not fall within the scope of software industry-specific accounting requirements. We have determined the embedded software within certain other products, primarily dispensing and respiratory products, is incidental to the products as a whole and therefore the accounting for these products also falls outside the scope of software-specific requirements. Generally, our standalone software application sales and any related post-contract support related to these sales are accounted for under the software industry-specific revenue recognition requirements.

### Accounting for Multiple-Element Arrangements

Some of our sales transactions qualify as multiple-element arrangements which require us to identify separate units of accounting within the arrangement and allocate the transaction consideration across these separate accounting units. For arrangements that include software and non-software elements, the transaction consideration is allocated to the software elements as a group as well as to the individual non-software elements that have been separately identified. The identification of accounting units and the allocation of total transaction consideration for multiple-element arrangements may be subjective and requires a degree of management judgment. Management’s judgments relative to multiple-element arrangements may significantly affect the timing of revenue recognition.

Transaction consideration for separately identified non-software units of accounting within an arrangement is recognized upon the completion of each deliverable based on its relative selling price. When applying the relative selling price method, the selling price of each deliverable is determined based upon the following hierarchy of evidence: vendor-specific objective evidence, which is generally based upon historical prices in stand-alone transactions; third-party evidence, which is generally based on market data on sales of similar products and services, if available; and management’s best estimate of selling price. Management’s best estimate of selling price is generally based upon the following considerations: stand-alone sales prices, established price lists, costs to produce, profit margins for similar products, market conditions, and customer stratification.

For software and software-related products, we use the relative fair value method to allocate transaction consideration to each unit of accounting; whereby the evidence used in the determination of fair value estimates are based solely on vendor-specific objective evidence. To the extent that vendor specific objective evidence does not exist for delivered elements of the transaction, we apply the residual method.

The revenue allocated to equipment or instruments in multiple-element arrangements is recognized upon transfer of title and risk of loss to the customer. The revenue allocated to extended warranty contracts and software maintenance contracts is deferred and recognized as these deliverables are performed under the arrangement. The majority of deferred revenue relating to extended warranty contracts is generally recognized within a few years whereas deferred revenue relating to software maintenance contracts is generally recognized over several years.

### Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time to time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, regulatory approvals, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future – including statements relating to volume growth, sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results – are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item 1A. Risk Factors in our 2014 Annual Report on Form 10-K.

- Weakness in the global economy and financial markets, and the potential adverse effect on the cost of operating our business, the demand for our products and services, the prices for our products and services due to increases in pricing pressure, or our ability to produce our products, including the impact on developing countries.
- Deficit reduction efforts or other adverse changes in the availability of government funding for healthcare and research, particularly in the United States and Europe, that could further weaken demand for our products and result in additional pricing pressures, as well as create potential collection risks associated with such sales.
- Risks relating to our acquisition of CareFusion, including our ability to successfully combine and integrate the CareFusion operations in order to obtain the anticipated benefits and costs savings from the transaction, and the significant additional indebtedness we incurred in connection with the financing of the acquisition and the impact this increased indebtedness may have on our ability to operate the combined company.
- The consequences of the Patient Protection and Affordable Care Act in the United States, which implemented an excise tax on U.S. sales of certain medical devices, and which could result in reduced demand for our products, increased pricing pressures or otherwise adversely affect our business.
- Future healthcare reform in the countries in which we do business that may involve changes in government pricing and reimbursement policies or other cost containment reforms.
- Changes in domestic and foreign healthcare industry practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare providers and trends toward managed care and healthcare cost containment. For example, changes to guidelines providing for increased cervical cancer screening intervals has and may continue to negatively impact sales of our Women’s Health and Cancer platform.
- Changes in reimbursement practices of third-party payers.
- Our ability to penetrate emerging markets, which depends on local economic and political conditions, and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities and distribution networks. Our international operations also increase our compliance risks, including risks under the Foreign Corrupt Practices Act and other anti-corruption laws.
- Political conditions in international markets, including civil unrest, terrorist activity, governmental changes, trade barriers, restrictions on the ability to transfer capital across borders and expropriation of assets by a government.
- Security breaches of our computer and communications systems, including computer viruses, “hacking” and “cyber-attacks,” which could impair our ability to conduct business, or result in the loss of BD trade secrets or otherwise compromise sensitive information of BD or its customers, suppliers and other business partners.
- Fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain components, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers), and the potential adverse effects of any disruption in the availability of such items.
- Regional, national and foreign economic factors, including inflation, deflation, fluctuations in interest rates and, in particular, foreign currency exchange rates, and the potential effect on our revenues, expenses, margins and credit ratings.
- New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, environmental protection, price controls and licensing and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.
- Product efficacy or safety concerns regarding our products resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (FDA) or foreign counterparts, declining sales and product liability claims, particularly in light of the current regulatory environment, including increased enforcement activity by the FDA. As a result of the CareFusion acquisition, we are operating under a consent decree with the FDA relating to our U.S. infusion pump business. The consent decree authorizes the FDA, in the event of any violations in the future, to order us to cease manufacturing and distributing products, recall products or take other actions, and we may be required to pay significant monetary damages if we fail to comply with any provision of the consent decree.
- Competitive factors that could adversely affect our operations, including new product introductions (for example, new forms of drug delivery) by our current or future competitors, increased pricing pressure due to the impact of low-cost manufacturers as certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs, patents attained by competitors (particularly as patents on our products expire), and new entrants into our markets.
- The effects of events that adversely impact our ability to manufacture our products (particularly where production of a product line is concentrated in one or more plants) or our ability to source materials or components from suppliers (including sole-source suppliers) that are needed for such manufacturing, including pandemics, natural disasters, or environmental factors.
- Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and

abroad, obtain intellectual property protection for our products, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product. Delays in obtaining necessary approvals or clearances from the FDA or other regulatory agencies or changes in the regulatory process may also delay product launches and increase development costs.

- Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.
- Fluctuations in university or U.S. and international governmental funding and policies for life sciences research.
- Our ability to achieve our projected level or mix of product sales, as our earnings forecasts are based on projected sales volumes and pricing of many product types, some of which are more profitable than others.
- Our ability to complete the implementation of our ongoing upgrade of our enterprise resource planning system, as any delays or deficiencies in completing the implementation could adversely affect our business.
- Pending and potential future litigation or other proceedings adverse to BD, including antitrust, product liability, environmental and patent infringement, and the availability or collectability of insurance relating to any such claims.
- The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.
- The effect of market fluctuations on the value of assets in BD’s pension plans and on actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.
- The impact of business combinations, including any volatility in earnings relating to acquired in-process research and development assets, and our ability to successfully integrate any business we may acquire.
- Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
- Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

## Controls and procedures

As filed, 1,386 characters.

An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of June 30, 2015. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities. On March 17, 2015, BD completed the acquisition of CareFusion Corporation (“CareFusion”). BD has extended its oversight and monitoring processes that support our internal control over financial reporting, as well as its disclosure controls and procedures, to include CareFusion’s operations. BD is continuing to integrate the acquired operations of CareFusion. There were no other changes in our internal control over financial reporting during the fiscal quarter ended June 30, 2015 identified in connection with the above-referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting.

## Risk factors

As filed, 172 characters.

There were no material changes in the risk factors previously disclosed in Part I, Item 1A, of our 2014 Annual Report on Form 10-K during the period covered by this report.

Filed Aug 6, 2015.
Source: SEC EDGAR, the filing index for accession 0001193125-15-280441. Last ingested by Listed: Nov 11, 2026, 03:43 ET. No prices; not investment advice.
